Innate Pharma announces the full exercise of the greenshoe in the context of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris

Innate Pharma SA, a biopharmaceutical company specialising in immunology and developing first-in-class* drugs targeting the innate immune system, announces the full exercise of the over-allotment option (or “greenshoe”) in the context of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris.